|
1.
|
|
|
2.
|
|
13 p, 1.2 MB |
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
/
Alserawan, Leticia (Institut d'Investigació Biomèdica Sant Pau) ;
Anguera, Georgia (Institut d'Investigació Biomèdica Sant Pau) ;
Zamora, Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Serra, Jorgina (Institut d'Investigació Biomèdica Sant Pau) ;
Martinez-Martinez, Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Riudavets Melià, M. (Institut d'Investigació Biomèdica Sant Pau) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Barba Joaquin, Andrés (Institut d'Investigació Biomèdica Sant Pau) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Vidal, Silvia (Institut d'Investigació Biomèdica Sant Pau)
Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a consequence of a breakdown in self-tolerance. ICIs can induce autoantibody formation, and the presence of antinuclear autoantibodies (ANAs) has been reported in patients who developed irAEs. [...]
2022 -  10.3390/ijms232012641
International journal of molecular sciences, Vol. 23 Núm. 20 (october 2022) , p. 12641
|
|
|
3.
|
|
12 p, 2.0 MB |
A multicentre validation study of the diagnostic value of plasma neurofilament light
/
Ashton, Nicholas J. (NIHR Biomedical Research Centre for Mental Health (Londres, Regne Unit)) ;
Janelidze, Shorena (Clinical Memory Research Unit. Department of Clinical Sciences Malmö. Lund University) ;
Al Khleifat, Ahmad (Department of Basic and Clinical Neuroscience. Maurice Wohl Clinical Neuroscience Institute. King's College London) ;
Leuzy, Antoine (Clinical Memory Research Unit. Department of Clinical Sciences Malmö. Lund University) ;
van der Ende, Emma L. (Alzheimer Center Rotterdam and Dept. of Neurology. Erasmus University Medical Center) ;
Karikari, Thomas K (Department of Psychiatry and Neurochemistry. Institute of Neuroscience & Physiology. The Sahlgrenska Academy at the University of Gothenburg) ;
Benedet, AndreaL. (Montreal Neurological Institute) ;
Pascoal, Tharick A. (Montreal Neurological Institute) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Parnetti, Lucilla (Laboratory of Clinical Neurochemistry. Neurology Clinic. University of Perugia) ;
Galimberti, Daniela (University of Milan) ;
Bonanni, Laura (Department of Neuroscience. Imaging and Clinical Sciences. University G.d'Annunzio of Chieti-Pescara) ;
Pilotto, Andrea (Parkinson's Disease Rehabilitation Centre. FERB ONLUS) ;
Padovani, Alessandro (Neurology Unit. Department of Clinical and Experimental Sciences. University of Brescia) ;
Lycke, Jan (Sahlgrenska University Hospital (Suècia)) ;
Novakova, Lenka (Sahlgrenska University Hospital (Suècia)) ;
Axelsson, Markus (Sahlgrenska University Hospital (Suècia)) ;
Velayudhan, Latha (Department of Health Sciences. University of Leicester) ;
Rabinovici, Gil D. (Department of Radiology & Biomedical Imaging. University of California) ;
Miller, Bruce L. (University of California San Francisco. Memory and Aging Center) ;
Pariante, Carmine M (Stress. Psychiatry and Immunology Lab & Perinatal Psychiatry. Maurice Wohl Clinical Neuroscience Institute. King's College London) ;
Nikkheslat, Naghmeh (King's College London (Regne Unit)) ;
Resnick, Susan M. (Brain Aging and Behavior Section. Laboratory of Behavioral Neuroscience. National Institute on Aging. National Institutes of Health) ;
Thambisetty, Madhav (Clinical and Translational Neuroscience Section. Laboratory of Behavioral Neuroscience. National Institute on Aging. National Institutes of Health) ;
Schöll, Michael (Department of Neurodegenerative Disease. Queen Square Institute of Neurology. University College London) ;
Fernández-Eulate, Gorka (Department of Neurology. Donostia University Hospital. Osakidetza) ;
Gil-Bea, Francisco J. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
López de Munain, Adolfo (Universidad del País Vasco. Departamento de Neurociencias) ;
Al-Chalabi, Ammar (King's College Hospital NHS Foundation Trust) ;
Rosa-Neto, Pedro (Montreal Neurological Institute) ;
Strydom, Andre (London Down Syndrome Consortium (LonDowns)) ;
Svenningsson, Per (Karolinska Institutet (Estocolm, Suècia). Department of Clinical Neuroscience) ;
Stomrud, Erik (Skåne University Hospital (Suècia)) ;
Santillo, Alexander (Lund University. Department of Clinical Sciences Malmö) ;
Aarsland, Dag (Stavanger University Hospital) ;
van Swieten, John C. (Erasmus University Medical Center) ;
Palmqvist, Sebastian (Lund University. Skåne University Hospital) ;
Zetterberg, Henrik (University College London. UK Dementia Research Institute) ;
Blennow, Kaj (Sahlgrenska University Hospital (Suècia)) ;
Hye, Abdul (Stavanger University Hospital) ;
Hansson, Oskar (Skåne University Hospital (Suècia))
Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in 13 neurodegenerative disorders, Down syndrome, depression and cognitively unimpaired controls from two multicenter cohorts: King's College London (n = 805) and the Swedish BioFINDER study (n = 1,464). [...]
2021 - 10.1038/s41467-021-23620-z
Nature communications, Vol. 12 Núm. 1 (january 2021) , p. 3400
|
|
|
4.
|
|
9 p, 283.5 KB |
Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis
/
Sainz, Luis (Institut d'Investigació Biomèdica Sant Pau) ;
Riera, Pau (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Moya, Patricia (Institut d'Investigació Biomèdica Sant Pau) ;
Bernal, Sara (Institut d'Investigació Biomèdica Sant Pau) ;
Casademont i Pou, Jordi (Institut d'Investigació Biomèdica Sant Pau) ;
Díaz Torne, César (Institut d'Investigació Biomèdica Sant Pau) ;
Millán, Ana Milena (Institut d'Investigació Biomèdica Sant Pau) ;
Park, Hye Sang (Institut d'Investigació Biomèdica Sant Pau) ;
Lasa, Adriana (Institut d'Investigació Biomèdica Sant Pau) ;
Corominas, Hèctor (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Tocilizumab is a first-line biologic disease-modifying anti-rheumatic drug (bDMARD) that inhibits the interleukin-6 (IL-6) pathway by antagonizing the IL-6 receptor (IL-6R). Tocilizumab is widely used to treat rheumatoid arthritis (RA), a prevalent autoimmune disease that can cause irreversible joint damage and disability. [...]
IIB.
2022 - 10.3390/jpm13010061
Journal of personalized medicine, Vol. 13 (december 2022)
|
|
|
5.
|
|
14 p, 3.9 MB |
Combined analysis of miR-200 family and its significance for breast cancer
/
Fontana, Andrea (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Barbano, Raffaela (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Dama, Elisa (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Pasculli, Barbara (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Rendina, Michelina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Morritti, Maria Grazia (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Melocchi, Valentina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Castelvetere, Marina (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Valori, Vanna Maria (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Ravaioli, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Bravaccini, Sara (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS) ;
Ciuffreda, Luigi (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Graziano, Paolo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Maiello, Evaristo (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Copetti, Massimiliano (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Fazio, Vito Michele (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Esteller, M (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bianchi, Fabrizio (Fondazione IRCCS Casa Sollievo della Sofferenza) ;
Parrella, Paola (Fondazione IRCCS Casa Sollievo della Sofferenza)
While the molecular functions of miR-200 family have been deeply investigated, a role for these miRNAs as breast cancer biomarkers remains largely unexplored. In the attempt to clarify this, we profiled the miR-200 family members expression in a large cohort of breast cancer cases with a long follow-up (H-CSS cohort) and in TCGA-BRCA cohort. [...]
2021 - 10.1038/s41598-021-82286-1
Scientific reports, Vol. 11 Núm. 1 (december 2021) , p. 2980
|
|
|
6.
|
|
15 p, 733.1 KB |
A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin
/
Moura, David S. (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Peña-Chilet, María (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Cordero Varela, Juan Antonio (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Alvarez-Alegret, Ramiro (Hospital Universitario Miguel Servet (Saragossa)) ;
Agra-Pujol, Carolina (Hospital General Universitario Gregorio Marañón) ;
Izquierdo, Francisco (Complejo Asistencial Universitario de León) ;
Ramos, Rafael (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ortega-Medina, Luis (Hospital Clínico San Carlos (Madrid)) ;
Martin-Davila, Francisco (Ciudad Real General Hospital) ;
Castilla-Ramirez, Carolina (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Hernandez-Leon, Carmen Nieves (Hospital Universitario de Canarias (La Laguna)) ;
Romagosa, Cleofe (Hospital Universitari Vall d'Hebron) ;
Vaz Salgado, María Ángeles (Hospital Universitario Ramón y Cajal (Madrid)) ;
Lavernia, Javier (Instituto Valenciano de Oncologia) ;
Bagué Rosell, Sílvia (Institut d'Investigació Biomèdica Sant Pau) ;
Mayodormo-Aranda, Empar (Hospital Universitari i Politècnic La Fe (València)) ;
Vicioso, Luis (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Hernández Barceló, José Emilio (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Rubio-Casadevall, Jordi (Hospital Universitari de Girona Doctor Josep Trueta) ;
de Juan, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Fiaño-Valverde, María Concepción (Hospital Álvaro Cunqueiro (Vigo)) ;
Hindi, Nadia (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Lopez-Alvarez, María (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Lacerenza, Serena (Universidad de Sevilla. Instituto de Biomedicina de Sevilla) ;
Dopazo, Joaquín (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Alvarez, Rosa (Hospital General Universitario Gregorio Marañón) ;
Valverde, Claudia (Hospital Universitari Vall d'Hebron) ;
Martínez-Trufero, Javier (Hospital Universitario Miguel Servet (Saragossa)) ;
Martín-Broto, Javier (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. [...]
2021 - 10.1002/1878-0261.12996
Molecular Oncology, Vol. 15 Núm. 12 (december 2021) , p. 3691-3705
|
|
|
7.
|
|
39 p, 1.3 MB |
Molecular Biomarkers in Cancer
/
Sarhadi, Virinder (University of Helsinki. Department of Oral and Maxillofacial Diseases) ;
Armengol Rosell, Gemma (Universitat Autònoma de Barcelona. Departament de Biologia Animal, de Biologia Vegetal i d'Ecologia)
Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer, occurrence of cancer, or patient outcome. They may include germline or somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. [...]
2022 - 10.3390/biom12081021
Biomolecules, Vol. 12, Issue 8 (August 2022) , art. 1021
|
|
|
8.
|
|
29 p, 1.4 MB |
Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer
/
Pardo, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Ruiz de Porras, Vicenç (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gil, Joan (Institut d'Investigació Biomèdica Sant Pau) ;
Font, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Puig Domingo, Manuel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Jordà, Mireia (Institut Germans Trias i Pujol)
Prostate cancer (PCa) is the most commonly diagnosed malignant neoplasm in men in the Western world. Localized low-risk PCa has an excellent prognosis thanks to effective local treatments; however, despite the incorporation of new therapeutic strategies, metastatic PCa remains incurable mainly due to disease heterogeneity and the development of resistance to therapy. [...]
2022 - 10.3390/nu14040851
Nutrients, Vol. 14 Núm. 4 (february 2022) , p. 851
|
|
|
9.
|
|
15 p, 691.2 KB |
Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients
/
Riera, Pau (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Rodríguez-Santiago, Benjamín (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Lasa, Adriana (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Gonzalez-Quereda, L. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Martín, Berta (Institut d'Investigació Biomèdica Sant Pau) ;
Salazar, Juliana (Institut d'Investigació Biomèdica Sant Pau) ;
Sebio, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Virgili, Anna C. (Institut d'Investigació Biomèdica Sant Pau) ;
Minguillón Pedreño, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Camps-Fajol, Cristina (Institut d'Investigació Biomèdica Sant Pau) ;
Surrallés i Calonge, Jordi (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau)
Background: About 40% of RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients undergoing anti-EGFR-based therapy have poor outcomes. Treatment failure is not only associated with poorer prognosis but higher healthcare costs. [...]
2020 - 10.3390/cancers12082245
Cancers, Vol. 12, Num. 8 (August 2020) , art. 2245
|
|
|
10.
|
|
10 p, 687.1 KB |
A framework for genomic biomarker actionability and its use in clinical decision making
/
Vidwans, Smruti J. (CollabRx Inc. (USA)) ;
Turski, Michelle L. (CollabRx Inc. (USA)) ;
Janku, Filip (University of Texas. MD Anderson Cancer Center (USA)) ;
Garrido-Laguna, Ignacio (University of Utah. Huntsman Cancer Institute (USA)) ;
Munoz, Javier (Banner MD Anderson Cancer Center (USA)) ;
Schwab, Richard (University of California. Moores Cancer Center (USA)) ;
Subbiah, Vivek (University of Texas. MD Anderson Cancer Center (USA)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Kurzrock, Razelle (University of California. Moores Cancer Center (USA)) ;
Universitat Autònoma de Barcelona
The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e. [...]
2014 - 10.18632/oncoscience.90
Oncoscience, Vol. 1, Núm. 10 (October 2014) , p. 614-623
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
